Sitagliptin Improves the Impaired Acute Insulin Response during a Meal Tolerance Test in Japanese Patients with Type 2 Diabetes Mellitus: A Small-Scale Real-World Study

详细信息    查看全文

• 作者：Tsuyoshi Ohkura (1)
  Youhei Fujioka (1)
  Keisuke Sumi (1)
  Risa Nakanishi (1)
  Hideki Shiochi (1)
  Naoya Yamamoto (1)
  Kazuhiko Matsuzawa (2)
  Shoichiro Izawa (1)
  Hiroko Ohkura (2)
  Masahiko Kato (1)
  Shin-ichi Taniguchi (2)
  Kazuhiro Yamamoto (1)
  
• 关键词：Dipeptidyl peptidase ; 4 (DPP ; 4) inhibitor ; Insulinogenic index ; Japanese ; Meal tolerance test ; Plasma glucose ; Plasma insulin ; Real world ; Sitagliptin ; Type 2 diabetes mellitus
• 刊名：Diabetes Therapy
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：5
• 期：1
• 页码：285-297
• 全文大小：579 KB
• 参考文献：1. DeFronzo RA. Lilly lecture 1987. The triumvirate beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1987;1988(37):667-7.
  2. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia. 2005;48:616-0. CrossRef
  3. Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res. 2004;36:867-6. CrossRef
  4. Ahren B, Holst JJ, Martensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol. 2000;404:239-5. CrossRef
  5. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:2078-4. CrossRef
  6. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91:4612-. CrossRef
  7. Aaboe K, Knop FK, Vilsb?ll T, et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2010;12:323-3. CrossRef
  8. Azuma K, Rádiková Z, Mancino J, et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:459-4. CrossRef
  9. Kadowaki T, Miyake Y, Kajinuma H. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia. 1984;26:44-. CrossRef
  10. Kadowaki T, Yoshinaga H. Risk factors for the development of non-insulin-dependent diabetes mellitus (NIDDM) in Japan. Diabetes Res Clin Pract. 1994;24:123-. CrossRef
  11. Fujimoto WY. Overview of non-insulin dependent diabetes mellitus (NIDDM) in different population groups. Diabet Med. 1996;13:7-0. CrossRef
  12. Kodama K, Tojjar D, Yamada S, Toda K, Patel CJ, Butte AJ. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabet Care. 2013;36:1789-6. CrossRef
  13. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabet Res Clin Pract. 2008;79:291-. CrossRef
  14. Iwamoto Y, Taniguchi T, Nonaka K, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J. 2010;57:383-4. CrossRef
  15. Herman GA, Mistry GC, Yi B, Bergman AJ, Wang AQ, Zeng W, Chen L, Snyder K, Ruckle JL, Larson PJ, Davies MJ, Langdon RB, Gottesdiener KM, Wagner JA. Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males. Br J Clin Pharmacol. 2011;71:429-6. CrossRef
  16. Yoshino G, Tominaga M, Hirano T, et al. The test meal A: a pilot model for the international standard of test meal for an assessment of both postprandial hyperglycemia and hyperlipidemia. J Jpn Diabetes Soc. 2006;49:361-1.
  17. Kuzuya T, Nakagawa S, Satoh J, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabet Res Clin Pract. 2002;55:65-5. CrossRef
  18. Sacks DB. Carbohydrates. In: Burtis C, Ashwood E editors. Tietz textbook of clinical chemistry, 3rd ed. Philadelphia: WB Saunders; 1999. p. 750-08.
  19. Ohkura T, Shiochi H, Fujioka Y, et al. 20/(fasting C-peptide x fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol. 2013;12:21. CrossRef
  20. Sumi K, Ohkura T, Yamamoto N, et al. Long-term miglitol administration suppresses postprandial glucose-dependent insulinotropic polypeptide secretion. Diabetol Int. 2013;4:190-. CrossRef
  21. Ohkura T, Inoue K, Fujioka Y, et al. The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study. BMC Res Notes. 2013;6:453. CrossRef
  22. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest. 2012;3:39-0. CrossRef
  23. Seltzer HS, Allen EW, Herron AL Jr, Brennan MT. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest. 1967;46:323-5. CrossRef
  24. Matsuda A, Kuzuya T. The prevalence of low insulin responders to oral glucose load among groups with various patterns of family history of diabetes. Diabet Med. 1996;13:59-2. CrossRef
  25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-. CrossRef
  26. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabet Care. 1999;22:1462-0. CrossRef
  27. Lim S, An JH, Shin H, et al. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study. Clin Endocrinol (Oxf). 2012;77:215-3. CrossRef
  28. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabet Care. 2011;34:1249-7. CrossRef
  29. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56:696-08. CrossRef
  30. Park H, Park C, Kim Y, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother. 2012;46:1453-9. CrossRef
  31. Sell H, Blüher M, Kl?ting N, et al. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabet Care. 2013;36:4083-0. CrossRef
  32. Del Prato S, Tiengo A. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes Metab Res Rev. 2001;17:164-4. CrossRef
  33. Mulvey CK, McNeill AM, Girman CJ, et al. Differential associations of oral glucose tolerance test-derived measures of insulin sensitivity and pancreatic β-cell function with coronary artery calcification and microalbuminuria in type 2 diabetes. Diabet Care. 2014;37:124-3. CrossRef
  34. M?ller JB, Pedersen M, Tanaka H, et al. Body composition is main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians. Diabet Care. 2014;37:796-04. CrossRef
  35. Inagaki N, JDS/JADEC Committee for Standardized Incretin Measurement. Guideline for Incretin Measurement. http://www.jds.or.jp/uploads/photos/786.pdf. Accessed May 16, 2014.
  36. Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, Musser BJ, Davies MJ, Kaufman KD, Goldstein BJ. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7.
  37. Chung HS, Suh S, Kim MY, et al. Predictive factors of durability to sitagliptin: slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin. J Diabet Invest. 2014;5:51-. CrossRef
  38. Rijkelijkhuizen JM, Girman CJ, Mari A, et al. Classical and model-based estimates of beta-cell function during a mixed meal vs. an OGTT in a population-based cohort. Diabet Res Clin Pract. 2009;83:280-. CrossRef
  39. Gentilcore D, Chaikomin R, Jones KL, et al. Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes. J Clin Endocrinol Metab. 2006;91:2062-. CrossRef
  
• 作者单位：Tsuyoshi Ohkura (1)
  Youhei Fujioka (1)
  Keisuke Sumi (1)
  Risa Nakanishi (1)
  Hideki Shiochi (1)
  Naoya Yamamoto (1)
  Kazuhiko Matsuzawa (2)
  Shoichiro Izawa (1)
  Hiroko Ohkura (2)
  Masahiko Kato (1)
  Shin-ichi Taniguchi (2)
  Kazuhiro Yamamoto (1)
  
  1. Division of Cardiovascular Medicine, Endocrinology and Metabolism, Department of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, Yonago, Tottori, Japan
  2. Department of Regional Medicine, Tottori University Faculty of Medicine, Yonago, Tottori, Japan
  
• ISSN：1869-6961

文摘

Introduction Several studies have shown that dipeptidyl peptidase-4 (DPP-4) inhibitors improve insulin secretion during oral glucose tolerance tests. However, the effects of DPP-4 inhibitors on impaired acute insulin responses in the postprandial state in real-world settings are unknown. Therefore, we evaluated the effects of sitagliptin on the acute insulin responses in Japanese patients with type 2 diabetes mellitus (T2DM) using meal tolerance tests. Methods Twenty-one patients with T2DM were given a test meal (460?kcal), and plasma glucose and insulin were measured at 0, 30, 60, 120, and 180?min after the meal. The insulinogenic index of all of these patients was below 43.2. The postprandial profiles were assessed at baseline and after 3?months of treatment with 50?mg/day sitagliptin after a meal (n?=?11) or were untreated (control group; n?=?10). This study was a prospective, open-label, non-blinded, non-randomized, clinical study. Results Sitagliptin significantly decreased the plasma glucose levels at 60, 120, and 180?min, and significantly increased the plasma insulin levels at 0 and 30?min. There were no significant changes in glucose or insulin in the control group. The insulinogenic index increased significantly in the sitagliptin group compared with the control group (+16.7 vs. +0.1, P? Conclusion Administration of sitagliptin at 50?mg/day after a meal improved the impaired acute insulin response and suppressed postprandial hyperglycemia. Whereas the study is rather small and the design is suboptimal as it is not randomized and not blinded, these results suggest that sitagliptin is effective in Japanese patients with T2DM, many of whom display impaired acute insulin responses after a meal.